Metformin hydrochloride; sitagliptin phosphate - Generic Drug Details

What are the generic drug sources for metformin hydrochloride; sitagliptin phosphate and what is the scope of freedom to operate?

Metformin hydrochloride; sitagliptin phosphate is the generic ingredient in three branded drugs marketed by Msd Sub Merck, Ph Health, Apotex, and Sandoz, and is included in five NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Metformin hydrochloride; sitagliptin phosphate has sixty-one patent family members in forty countries.

Five suppliers are listed for this compound.

Summary for metformin hydrochloride; sitagliptin phosphate

International Patents:	61
US Patents:	2
Tradenames:	3
Applicants:	4
NDAs:	5
Finished Product Suppliers / Packagers:	5
Clinical Trials:	10
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for metformin hydrochloride; sitagliptin phosphate
DailyMed Link:	metformin hydrochloride; sitagliptin phosphate at DailyMed

Recent Clinical Trials for metformin hydrochloride; sitagliptin phosphate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nanfang Hospital, Southern Medical University	PHASE4
Zhibin Xu	PHASE4
University of Lahore	PHASE3

See all metformin hydrochloride; sitagliptin phosphate clinical trials

Pharmacology for metformin hydrochloride; sitagliptin phosphate

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for metformin hydrochloride; sitagliptin phosphate

A10BA	Biguanides
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUMET XR	Extended-release Tablets	metformin hydrochloride; sitagliptin phosphate	100 mg/1000 mg	202270	1	2012-10-22
JANUMET XR	Extended-release Tablets	metformin hydrochloride; sitagliptin phosphate	50 mg/500 mg and 50 mg/1000 mg	202270	1	2012-03-16
JANUMET	Tablets	metformin hydrochloride; sitagliptin phosphate	50 mg/500 mg and 50 mg/1000 mg	022044	5	2010-10-18

US Patents and Regulatory Information for metformin hydrochloride; sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	SITAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	204144-003	Jun 4, 2025	AB	RX	No	No
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes	8,414,921*PED				Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes	7,326,708*PED				Y

Expired US Patents for metformin hydrochloride; sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	6,340,475
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012	7,459,428
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012	7,459,428

International Patents for metformin hydrochloride; sitagliptin phosphate

Country	Patent Number	Title	Estimated Expiration
Argentina	044705	SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA -IV
Argentina	094185	SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV
Austria	373003

Supplementary Protection Certificates for metformin hydrochloride; sitagliptin phosphate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	132008901682802	Italy		PRODUCT NAME: SITAGLIPTIN/METFORMINA CLORIDRATO(JANUMET, VELMETIA, EFFICIB); AUTHORISATION NUMBER(S) AND DATE(S): JANUMET:EU/1/08/455/001... 014; VELMETIA:EU/1/08/456/001...014;EFFICIB: EU/1/08/457/001....014, 20080716;58450-01;58450-02; 58450-03, 20080408
1506211	CA 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
1506211	42/2014	Austria		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON UND METFORMIN UND EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/13/900 (MITTEILUNG) 20140121

Last updated: February 13, 2026

What Are the Current Market Dynamics for Metformin Hydrochloride and Sitagliptin Phosphate?

The market for antidiabetic drugs, especially metformin hydrochloride and sitagliptin phosphate, remains robust amid increasing diabetes prevalence. Metformin, as a first-line oral treatment for type 2 diabetes, dominates the market, while sitagliptin, a DPP-4 inhibitor, holds significant share as an adjunct therapy.

Market Size and Growth Trends

In 2022, the global metformin market was valued at approximately USD 4.3 billion. It projects a compound annual growth rate (CAGR) of 3.5% between 2023 and 2030, driven by rising type 2 diabetes cases and generic availability.

Sitagliptin accounted for an estimated USD 1.8 billion in 2022, with a CAGR forecast of 5%. Its market expansion aligns with broader adoption of DPP-4 inhibitors and newer agents, such as SGLT2 inhibitors.

Key Market Drivers

• Growth in type 2 diabetes prevalence: The International Diabetes Federation estimates 537 million adults affected globally in 2021, expected to reach 643 million by 2030.
• Generic drug availability: Metformin's patent expired in most jurisdictions, leading to price reductions and increased accessibility.
• Favorable safety profile: Both drugs are considered safe with manageable side effects, supporting widespread use.
• Physician adherence to guidelines: Guidelines endorse metformin as first-line therapy, supporting sustained demand.

Market Challenges

• Pricing pressures: Price competition among generics limits revenue growth.
• Regulatory hurdles: Variations in regulatory standards affect approval timelines.
• Competition from new drugs: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists are gaining market share due to cardio-renal benefits.

What Is the Financial Trajectory for Metformin Hydrochloride?

Revenue Trends

• 2022: USD 4.3 billion globally.
• 2023-2030: Expected to grow at CAGR 3.5%, reaching approximately USD 6 billion by 2030.

Profitability and Pricing

• Genericization has driven downward pressure on prices.
• Margins are narrowing but remain sufficient due to production scale and low-cost manufacturing.

Patent and Regulatory Environment

• No patents for metformin; generic manufacturers dominate.
• Stringent manufacturing standards imposed by FDA and EMA influence costs.

What Is the Financial Outlook for Sitagliptin Phosphate?

Revenue Trends

• 2022: USD 1.8 billion worldwide.
• 2023-2030: Anticipated CAGR of about 5%, with revenues potentially reaching USD 3 billion by 2030.

Market Share and Competition

• Sitagliptin experienced peak sales around 2015.
• Competition from other DPP-4 inhibitors (e.g., linagliptin, saxagliptin) affects market share.
• Entry of fixed-dose combinations with metformin enhances sales potential.

Pricing and Cost Structures

• Patent expiry in 2022 in the US led to biosimilar entries, reducing prices.
• Innovator companies focus on formulation improvements and combination therapies to sustain margins.

How Do Market Drivers and Challenges Impact Future Outlook?

The combination of rising diabetes prevalence and the established position of metformin ensures steady revenues, but pricing pressures from generics will constrain profit margins. Sitagliptin's growth depends on its ability to differentiate via combination formulations and positioning within the rapidly evolving diabetic treatment landscape.

The market will also be influenced by:

• Adoption of personalized medicine approaches.
• Regulatory pathways for biosimilars and generics.
• Competitive innovations from newer drug classes.

What Are the Key Takeaways?

• Metformin dominates the antidiabetic oral treatment market due to its efficacy, safety, and price competitiveness. Its revenue is expected to grow modestly, constrained by generic competition.
• Sitagliptin maintains a significant market share, with growth driven by drug combinations and increased adoption of DPP-4 inhibitors. Patent expiration has reduced prices, but new formulations and competitors temper growth.
• Both drugs will face continued pressure from emerging therapies with proven cardiovascular and renal benefits.
• Future profitability prospects hinge on product differentiation and market segment expansion through combination therapies.

FAQs

1. How will patent expirations influence the metformin market?
Patent expirations enable generics to enter the market, reducing prices and limiting revenue growth for branded formulations. The overall market size remains steady due to high demand but profit margins decline.

2. Can sitagliptin maintain its market share against newer therapies?
Yes, if it continues to expand through fixed-dose combinations with metformin and maintains a favorable safety profile. Competition from SGLT2 inhibitors and GLP-1 receptor agonists remains a concern.

3. What role do regulatory standards play in these markets?
Stringent standards from agencies like FDA and EMA impact manufacturing costs, approval processes, and market access, influencing pricing and product availability.

4. Are biosimilars likely to impact sitagliptin's future?
Biosimilars are less relevant for sitagliptin, which is a small-molecule drug, but biosimilar competition affects newer biologic agents in the diabetic space and indicates a trend toward cost reduction.

5. What innovations could alter the current market dynamics?
Development of combination pills, personalized treatment plans based on genetic markers, and therapies with confirmed cardiovascular benefits could shift market shares and revenue streams.

---

Sources

1. Grand View Research. "Metformin Market Size, Share & Trends Analysis." 2022.
2. GlobalData. "Sitagliptin Market Analysis." 2023.
3. International Diabetes Federation. "IDF Diabetes Atlas," 2021.
4. U.S. Food and Drug Administration. "Drug Approvals and Patent Data," 2022.
5. MarketWatch. "Antidiabetic Drug Market Forecast," 2023.